The development follows the World Health Organization’s prequalification of a newborn-specific formulation of artemether-lumefantrine, the first treatment tailored for infants weighing between two and five kilogrammes. The approval is seen as a long-awaited response to a critical gap in malaria care for the youngest and most vulnerable patients.
The announcement has drawn strong reactions from health professionals, including Ikotun Olayemi, President of the Nigeria Biochemistry Practitioners Association, who described the development as both scientifically significant and life-saving in its potential impact.
Speaking in Lagos during activities marking the 2026 World Malaria Day, Olayemi said the innovation represents a major shift in how infectious diseases are managed in neonates.
He said:
“The recent approval of a newborn-specific malaria drug by the World Health Organisation offered a major biochemical and public health benefit that could lead to the reduction of malaria deaths among infants in Nigeria.”
A long-standing treatment gap finally addressed
Until now, newborns diagnosed with malaria have typically been treated using formulations designed for older infants and children. Health experts have long warned that this practice carries risks, including incorrect dosing, drug toxicity, and unpredictable drug absorption in newborns whose organs — especially the liver — are still developing.
The WHO noted that this gap has affected millions of babies born annually in malaria-endemic regions, particularly across Africa, where an estimated 30 million newborns are at risk each year.
The newly prequalified drug is expected to help correct that imbalance by providing age- and weight-specific dosing designed for infants between two and five kilogrammes, reducing the risks associated with off-label use of paediatric treatments.
WHO officials explained that prequalification means the medicine has met international standards for quality, safety, and effectiveness, enabling governments to procure it for public health programmes.
Why experts say it matters for Nigeria
For Nigeria, where malaria remains one of the leading causes of infant mortality, the potential impact could be substantial if the drug is effectively rolled out.
Olayemi said the development goes beyond a pharmaceutical milestone and reflects a shift toward more precise, biology-driven treatment models for newborns.
“It represents a shift toward precision medicine in infectious disease management tailored specifically for neonates who require specialised dosing considerations,” he said.
He added that proper adoption could reduce malaria-related deaths in early infancy, but warned that weak implementation systems could limit its reach in rural and underserved communities.
From safer dosing to new research opportunities
Beyond its immediate clinical benefits, Olayemi noted that the new treatment opens up opportunities for Nigerian researchers in biochemistry and pharmacology.
He said it could strengthen local capacity in drug metabolism studies, particularly in understanding how newborns process anti-malarial drugs differently from older children.
He also suggested that it could encourage further exploration of complementary treatments, including plant-based compounds, as adjuncts to conventional malaria therapy — a field that has long been of interest in African biomedical research.
Calls for government and WHO collaboration
The biochemistry association president urged the WHO and Nigerian authorities to ensure that the drug is both affordable and widely accessible, particularly in rural clinics and primary healthcare centres where malaria burden is often highest.
He also called for expanded professional training for healthcare workers, including biochemists, pharmacists, and clinicians, to ensure safe administration and proper understanding of neonatal pharmacology.
“We urge collaboration to ensure affordable distribution and availability across rural clinics, primary healthcare centres and biochemistry practice facilities nationwide,” he said.
Emphasis on monitoring and long-term safety
While describing the drug as “scientifically sound and potentially lifesaving,” Olayemi stressed the importance of ongoing monitoring once it is introduced into routine use.
He called for sustained pharmacovigilance, continuous research, and population-specific evaluation to track safety and effectiveness in real-world settings.
A cautious but hopeful step forward
The introduction of a newborn-specific malaria treatment marks a significant milestone in global efforts to reduce preventable infant deaths from the disease.
However, experts emphasise that its success will depend not only on scientific approval, but also on how effectively it is integrated into national health systems, distributed across high-burden regions, and supported with adequate training and monitoring.
For now, health professionals view it as a promising step toward closing one of the most persistent gaps in malaria treatment — one that has left the youngest patients historically underserved in the fight against the disease.